Wednesday, August 19, 2015 4:01:12 AM
A few highlights from the website.
MVax® for the Treatment of Melanoma
AVAX's Phase III Study
AVAX plans to launch an International Phase III Registration trial with its lead product MVax® by the end of the year. The Phase III study will enroll approximately 400 patients. AVAX has met with the United States Food and Drug Administration ("FDA") on the study design and has plans to continue to work with FDA to be able to focus and re-launch this pivotal clinical study.
The protocol will be based on published data showing that administration of MVax® alone can induce clinically meaningful anti-tumor responses in patients with stage III and IV melanoma.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM